Clinics that prescribe both semaglutide and tirzepatide often use one intake workflow for both drugs. This can leave the chart unable to show how GLP-1 good faith exam requirements were applied to the medication selected.
This guide explains the shared requirements, drug-specific screening differences, provider eligibility, state variations, and documentation standards clinics need to understand.
GLP-1 Good Faith Exam Requirements: The Non-Negotiable Baseline
Whatever term a state uses, a defensible evaluation should clearly answer three questions:
- Who evaluated the patient? The clinician must be licensed or otherwise authorized where the patient is located and permitted to make the prescribing decision.
- What did the evaluation include? The chart should show relevant history, objective information, medication review, risk assessment, and an individualized treatment decision. A SOAP note can organize the evidence, but a form cannot replace clinical judgment.
- When must it be updated? Reassessment depends on state rules, clinical changes, treatment response, medication changes, and the applicable standard of care.
An intake questionnaire, signed waiver, or blanket approval can support the encounter but cannot establish the patient-provider relationship alone. The same baseline applies to Good Faith Exams for weight loss clinics.
Semaglutide vs Tirzepatide GFE Requirements, Side by Side
The verdict is direct: evaluator authority, telehealth rules, documentation standards, lab principles, and reassessment do not change merely because the molecule changes. Medication-specific screening and counseling do.
| GFE Dimension | Semaglutide | Tirzepatide | Verdict |
| Mechanism | GLP-1 receptor agonist | Dual GIP and GLP-1 agonist | Different |
| Eligible evaluator | Set by patient-state law | Set by patient-state law | Same |
| Telehealth format | Set by patient-state law | Set by patient-state law | Same |
| Core contraindications | MTC, MEN2, hypersensitivity | MTC, MEN2, hypersensitivity | Same |
| Counseling emphasis | Semaglutide-specific label issues | Includes oral contraceptive counseling | Different |
| Labwork | Based on patient and indication | Based on patient and indication | Same principle |
| Compounded product | Separate 503A or 503B analysis | Separate 503A or 503B analysis | Same framework |
| Reassessment | State and patient specific | State and patient specific | Same principle |
Review the Good Faith Exam for semaglutide and Good Faith Exam for tirzepatide for medication-level detail.
Good Faith Exam for GLP-1 Prescribing: Who Holds the Pen
A good faith exam for GLP-1 prescribing must end with a decision from a professional authorized under the law where the patient is located.
- MD or DO: May evaluate and prescribe when appropriately licensed and acting within applicable law.
- NP: May act independently only where full-practice authority and other state rules permit. Collaboration or supervision may apply elsewhere.
- PA: May evaluate and prescribe within state scope, delegation, and supervision requirements.
- RN, MA, or esthetician: May collect information within scope but cannot independently diagnose, determine medical necessity, or authorize the prescription.
The Contraindications and Warnings That Must Change the Decision
Both products are contraindicated for a personal or family history of medullary thyroid carcinoma or MEN2. Hypersensitivity contraindications also apply, with label-specific wording. Document review of:
- pancreatitis history or symptoms;
- severe gastroparesis or serious gastrointestinal disease;
- gallbladder disease, dehydration, and renal risks;
- pregnancy, planned pregnancy, or breastfeeding;
- insulin or secretagogue use and hypoglycemia risk;
- diabetic retinopathy and monitoring needs;
- planned anesthesia or deep sedation; and
- concurrent medications and interactions.
One difference matters: tirzepatide labeling advises patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for four weeks after starting treatment and each dose increase.
Check current product labeling for Wegovy (semaglutide) and Zepbound (tirzepatide) for the most current contraindications, warnings, and drug interactions.
What Your Chart Has to Prove When a Board Looks
GLP-1 good faith exam compliance lives in the chart. Use one core template with medication-specific fields:
- History: Diagnosis, prior treatment, symptoms, medications, allergies, family history, and reproductive considerations.
- Objective support: Identity, location, weight or BMI, relevant findings, and justified labs.
- Drug assessment: Indication, contraindications, warnings, interactions, formulation, and candidacy.
- Decision and plan: Rationale, dose, monitoring, follow-up, and escalation instructions.
- Consent: Benefits, material risks, alternatives, and patient questions.
GLP-1 GFE compliance by drug means shared baseline fields plus medication-specific proof of judgment. GLP-1 good faith exam requirements cannot be met by a waiver alone.
Compounded products require a separate pharmacy-law review. The chart should identify the formulation, source pharmacy or outsourcing facility, and patient-specific prescribing rationale. Verify current federal and state requirements for the product and fulfillment model.
Where the Rules Change at the State Line
Many boards do not use “Good Faith Exam” as the controlling term. They regulate the patient-provider relationship, prescribing standard of care, telemedicine, professional scope, and documentation.
State differences may affect:
- whether synchronous video, asynchronous review, or an in-person encounter is sufficient;
- when an in-person examination is triggered;
- whether an NP may practice independently;
- what supervision or delegation a PA requires;
- what license or telemedicine registration the prescriber needs; and
- when reassessment or renewed consent is required.
Verify current medical, nursing, physician assistant, pharmacy, and telehealth requirements in every state where patients are located. National model policies can inform a workflow, but they do not replace binding state law.
The Documentation Gaps That Put Clinics at Risk
A one-size intake can collect shared facts. It is not enough for the medication-specific decision layer. Common failures include:
- using one generic assessment without naming the selected drug;
- treating a questionnaire, BMI result, or waiver as the examination;
- omitting contraindication, warning, interaction, or pregnancy screening;
- recording patient preference without the clinician’s rationale;
- leaving the formulation, source pharmacy, or compounding status unclear;
- relying on the initial exam despite material health or treatment changes; and
- failing to document consent, follow-up, or the reason for denial.
A completed evaluation also does not require the clinician to approve treatment. Review whether a Good Faith Exam guarantees approval before building automatic clearance into the workflow.
Final Thoughts: Treat the Exam Like the Prescription Depends on It
Semaglutide and tirzepatide do not need separate legal rulebooks. They need one reliable evaluation framework that produces medication-specific screening, counseling, judgment, and documentation before prescribing.
That is the operational standard behind GLP-1 good faith exam requirements: the chart should show who evaluated the patient, why the selected drug was or was not appropriate, and what happens next. See how Good Faith Exams for GLP-1 clinics can fit into a two-drug workflow without reducing the clinical decision to a checkbox.
Frequently Asked Questions
Do semaglutide and tirzepatide require the same Good Faith Exam process?
Generally, yes. GLP-1 good faith exam requirements use the same patient-state legal and professional framework for both drugs. The evaluation must still address the warnings, interactions, formulation, counseling, and clinical reasoning relevant to the medication selected.
What are the key differences in GFE requirements between GLP-1 drugs?
The legal framework usually does not change by molecule. GLP-1 GFE compliance by drug means using semaglutide vs tirzepatide GFE requirements to guide medication-specific screening, interaction review, counseling, formulation assessment, and prescribing rationale.
Who can perform a Good Faith Exam for GLP-1 prescribing?
The evaluation should be performed by an MD, DO, NP, or PA authorized under the patient’s state law. Licensing, scope, supervision, collaboration, delegation, and prescriptive authority still apply.
Can a GLP-1 Good Faith Exam be completed via telehealth?
Sometimes. A telehealth good faith exam GLP-1 workflow must comply with the law where the patient is located and gather enough information to meet the standard of care. Permitted modalities and in-person triggers vary by state.
What contraindications apply specifically to GLP-1 receptor agonists?
Both products are contraindicated for a personal or family history of MTC or MEN2. Hypersensitivity contraindications also apply under each label. Pancreatitis, severe gastroparesis, pregnancy, renal risk, and other warnings require assessment.
How often does a GLP-1 patient need an updated Good Faith Exam?
No single nationwide cadence is created by the drug name. Reassessment depends on state requirements, the standard of care, clinical changes, adverse effects, dose or medication changes, and the provider’s documented follow-up plan.
What documentation should a GLP-1 clinic keep after a GFE?
For GLP-1 good faith exam compliance, retain the history, objective findings, risk screening, diagnosis, medication-specific rationale, treatment plan, consent, follow-up, and provider identity. Follow applicable record-retention and privacy requirements.
Does the type of GLP-1 drug change who must perform the GFE?
Usually not. Performer eligibility comes from patient-state law, professional scope, supervision or collaboration requirements, and prescribing authority, not whether the clinician selects semaglutide or tirzepatide.
Can a nurse practitioner perform GLP-1 Good Faith Exams independently?
Only when the patient’s state grants the NP the necessary independent authority and the NP meets all licensing and prescribing conditions. Reduced- or restricted-practice states may require collaboration, supervision, or another formal relationship.
What state-level rules affect GLP-1 GFE requirements?
State rules may govern licensure, patient location, telehealth modality, in-person triggers, prescribing authority, NP or PA practice, documentation, and reassessment. Confirm current requirements with the relevant boards and qualified healthcare counsel.
How should a clinic document a patient’s diabetes or obesity history in the GFE?
The GFE before GLP-1 treatment should record diagnosis, weight trajectory, prior therapies, comorbidities, current medications, relevant complications, and treatment goals. The assessment should explain how those facts support, limit, or rule out prescribing.
What happens if a GLP-1 clinic skips the Good Faith Exam?
The clinic may lack evidence of a valid evaluation and patient-specific prescribing decision. That gap increases exposure during a complaint, audit, adverse event, or licensing review. Consequences depend on the governing state and facts.
